Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 63 of 95, showing 5 Applications out of 471 total, starting on record 311, ending on 315

# Protocol No Study Title Investigator(s) & Site(s)

311.

ECCT/22/10/03   ISSC
    A randomized, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics, and efficacy of escalating doses of oral ivermectin in scabies infected children weighing 5 to less than 15 kilograms in Kenya   
Principal Investigator(s)
1. Eunice Akinyi Ouma
Site(s) in Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital
 
View

312.

ECCT/21/07/06   GBT132_Inclacumab-Ps 3 Trial
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Fredrick Asirwa Chite
2. Videlis N Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Strathmore University Medical Centre (Nairobi City county)
 
View

313.

ECCT/21/12/07   GBT 132- Inclacumab Phase 3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Videlis N Nduba
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
 
View

314.

ECCT/22/03/09   GBT 132-Inclacumub PH3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Videlis N Nduba
2. Bernhards Ragama Ogutu
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. KEMRI Siaya Clinical Research Annex (Siaya county)
2. KEMRI/CRDR (Nairobi City county)
3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county)
4. Strathmore University Medical Centre (Nairobi City county)
 
View

315.

ECCT/21/05/05   The “EMPATHY” Trial
    A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19.       
Principal Investigator(s)
1. DR LUCAS OTIENO TINA
2. Dr. Bernhards Ragama Ogutu
3. Dr Deborah Chepngeno Langat
4. Dr Videlis Nduba Nduba
5. Dr Janet Oyieko
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. Kenyatta University Teaching Referral and Research Hospital (KUTRRH) (Nairobi City county)
3. Kenya Medical Research Institute/US Army Medical Research Directorate-Kenya-Kericho (Kericho county)
4. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
5. KEMRI-USAMRD-A, Kisumu Field Station (Kisumu county)
 
View